Last reviewed · How we verify
losartan / Duration of Treatment: 6 weeks
losartan / Duration of Treatment: 6 weeks is a Small molecule drug developed by Organon and Co. It is currently in Phase 3 development.
At a glance
| Generic name | losartan / Duration of Treatment: 6 weeks |
|---|---|
| Sponsor | Organon and Co |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Losartan + Sunitinib in Treatment of Osteosarcoma (PHASE1)
- Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB (PHASE4)
- MK0954A-264 Filter Study (0954A-264)(COMPLETED) (PHASE3)
- Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- losartan / Duration of Treatment: 6 weeks CI brief — competitive landscape report
- losartan / Duration of Treatment: 6 weeks updates RSS · CI watch RSS
- Organon and Co portfolio CI
Frequently asked questions about losartan / Duration of Treatment: 6 weeks
What is losartan / Duration of Treatment: 6 weeks?
losartan / Duration of Treatment: 6 weeks is a Small molecule drug developed by Organon and Co.
Who makes losartan / Duration of Treatment: 6 weeks?
losartan / Duration of Treatment: 6 weeks is developed by Organon and Co (see full Organon and Co pipeline at /company/organon-and-co).
What development phase is losartan / Duration of Treatment: 6 weeks in?
losartan / Duration of Treatment: 6 weeks is in Phase 3.